Insight Molecular Diagnostics Inc. Ordinary Shares IMDX 深 沪
等待开盘 07-21 09:30:00 美东时间
2.86
+0.030
+1.06%
华盛通- 最 高2.9199
- 今 开2.83
- 成交量 2.46万股
- 最 低 2.82
- 昨 收 2.83
- 总市值 8179.40万
- 52周最高 4.75
- 市盈率 静 --
- 换手率 0.09%
- 52周最低 1.922
- 委 比 -65.92%
- 总股本 2859.93万
- 历史最高 204.80
- 量 比 0.55
- 振 幅 3.53%
- 历史最低 1.922
- 每 手 1
- 风险率
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多InspireMD Announces U.S. Commercial Launch of CGuard® Prime Carotid Stent System for the Prevention of Stroke
<p>Inspeq News</p> <p>Inspeq has launched the CGuard Prime carotid stent system in the U.S. following FDA approval. The system features a dual-layer design, MicroNet mesh, and SmartFit technology to minimize embolism risk. With double-digit market share in over 30 countries, the company aims to expand its presence in the U.S. using a seasoned commercial team. Experts laud the device for its advanced embolic protection and ease of use, offering ...
07-09 11:00
iMDx Reports Results From Study Evaluating Flagship Test Kit Technology In Head-to-head Comparison With Another Commercially Available Test Kit.
Study indicates iMDx flagship technology's equivalence with commercially available dd-cfDNA test kitsHead-to-head comparison of iMDx's digital PCR-based test kits with NGS kits shows consistent results in 96 transplant
06-24 04:06
iMDx Reports Strong Head-to-Head Data in Kidney Transplant Rejection Testing
Insight Molecular Diagnostics (iMDx) announced positive results from a study comparing its digital PCR-based test kit (GraftAssureIQ) with next-generation sequencing (NGS) kits for detecting donor-derived cell-free DNA (dd-cfDNA). The study, involving 96 kidney transplant patients, showed equivalent results in measuring dd-cfDNA levels, a key biomarker for transplant rejection. iMDx's technology demonstrated improved analytical sensitivity, parti...
06-23 20:05
